On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

Why Seer sees its nanoparticles as the path to population-scale unbiased proteomics

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year.

On Wednesday, Seer announced a series D-1 round led by Fidelity Management and Research Company, which included new investor HBM Healthcare Investments and all previous investors. Last year, the company said it was aiming for a 2021 launch when it raised another $55 million

Read the full 725 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE